Literature DB >> 18308964

Challenges in pulmonary fibrosis: 8--The need for an international registry for idiopathic pulmonary fibrosis.

J W Wilson1, R M du Bois, T E King.   

Abstract

Improved survival from idiopathic pulmonary fibrosis (IPF) is dependent on better understanding of the epidemiology of the disease, its diagnostic spectrum in global terms and an analysis of outcomes from emerging therapies at a significant level. Outside major lung transplant centres, few institutions have significant numbers to provide this information. Relevant examples exist to justify the establishment of registry data to achieve these aims. The gains seen in cystic fibrosis, lymphangioleiomyomatosis and lung transplantation over the past decade stem from optimisation of treatment plans through registry data. We advocate for an international registry to achieve better outcomes in IPF.

Entities:  

Mesh:

Year:  2008        PMID: 18308964     DOI: 10.1136/thx.2004.031062

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  9 in total

Review 1.  Therapeutic update in idiopathic pulmonary fibrosis.

Authors:  Andrew L Chan; Rokhsara Rafii; Samuel Louie; Timothy E Albertson
Journal:  Clin Rev Allergy Immunol       Date:  2013-02       Impact factor: 8.667

Review 2.  Clinical use of biomarkers of survival in pulmonary fibrosis.

Authors:  Michiel Thomeer; Jan C Grutters; Wim A Wuyts; Stijn Willems; Maurits G Demedts
Journal:  Respir Res       Date:  2010-06-28

3.  Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry.

Authors:  Jürgen Behr; Michael Kreuter; Marius M Hoeper; Hubert Wirtz; Jens Klotsche; Dirk Koschel; Stefan Andreas; Martin Claussen; Christian Grohé; Henrike Wilkens; Winfried Randerath; Dirk Skowasch; F Joachim Meyer; Joachim Kirschner; Sven Gläser; Felix J F Herth; Tobias Welte; Rudolf Maria Huber; Claus Neurohr; Martin Schwaiblmair; Martin Kohlhäufl; Gert Höffken; Matthias Held; Andrea Koch; Thomas Bahmer; David Pittrow
Journal:  Eur Respir J       Date:  2015-04-02       Impact factor: 16.671

4.  Investigating significant health trends in idiopathic pulmonary fibrosis (INSIGHTS-IPF): rationale, aims and design of a nationwide prospective registry.

Authors:  Juergen Behr; Marius M Hoeper; Michael Kreuter; Jens Klotsche; Hubert Wirtz; David Pittrow
Journal:  BMJ Open Respir Res       Date:  2014-01-03

5.  The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis.

Authors:  Andreas Guenther; Ekaterina Krauss; Silke Tello; Jasmin Wagner; Bettina Paul; Stefan Kuhn; Olga Maurer; Sabine Heinemann; Ulrich Costabel; María Asunción Nieto Barbero; Veronika Müller; Philippe Bonniaud; Carlo Vancheri; Athol Wells; Martina Vasakova; Alberto Pesci; Matteo Sofia; Walter Klepetko; Werner Seeger; Fotios Drakopanagiotakis; Bruno Crestani
Journal:  Respir Res       Date:  2018-07-28

6.  Baseline clinical characteristics, comorbidities and prescribed medication in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry.

Authors:  Wim A Wuyts; Caroline Dahlqvist; Hans Slabbynck; Marc Schlesser; Natacha Gusbin; Christophe Compere; Sofie Maddens; Klaus-Uwe Kirchgaessler; Karen Bartley; Benjamin Bondue
Journal:  BMJ Open Respir Res       Date:  2018-11-21

7.  The histone methyltransferase DOT1L is a new epigenetic regulator of pulmonary fibrosis.

Authors:  Di Yang; Peng Xu; Haibi Su; Wen Zhong; Jie Xu; Zhenghua Su; Xinhua Liu
Journal:  Cell Death Dis       Date:  2022-01-17       Impact factor: 8.469

8.  Differences in Baseline Characteristics and Access to Treatment of Newly Diagnosed Patients With IPF in the EMPIRE Countries.

Authors:  Abigél Margit Kolonics-Farkas; Martina Šterclová; Nesrin Mogulkoc; Katarzyna Lewandowska; Veronika Müller; Marta Hájková; Mordechai Kramer; Dragana Jovanovic; Jasna Tekavec-Trkanjec; Michael Studnicka; Natalia Stoeva; Simona Littnerová; Martina Vašáková
Journal:  Front Med (Lausanne)       Date:  2021-12-23

9.  Longitudinal clinical outcomes in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry.

Authors:  Wim A Wuyts; Caroline Dahlqvist; Hans Slabbynck; Marc Schlesser; Natacha Gusbin; Christophe Compere; Sofie Maddens; Yuan-Chi Lee; Klaus-Uwe Kirchgaessler; Karen Bartley; Benjamin Bondue
Journal:  Respir Res       Date:  2019-10-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.